Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01204918 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Tolerability of Riluzole in Treatment Resistant Depression
A Phase 2 study of Depression, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
- 3
- Study locations
NCT01204918: Completed Phase 2 study of Depression, sponsored by Yale University.
NCT01204918 is a Phase 2 study of Depression that has completed, run by Yale University. The registered enrollment target is 104 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01204918, a Phase 2 study of Depression, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study aims to examine the antidepressant efficacy of riluzole, employing a randomized, double-blind, placebo-controlled, adjunctive trial in treatment-resistant major depressive disorder (TRD).
Primary Outcome
This 10 item instrument is completed by the clinician by using a structured interview and defined anchor points, and aims to quantify the degree of depression over the past 7 days. The MADRS is a widely studied instrument for depression, and its reliability and validity are high. This instrument is administered at every study visit during the double-blind RCT, and at the screening, and baseline. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The over
Conditions Studied
Interventions
- DRUG placebo
- DRUG Riluzole
Study Locations (3)
Connecticut
- Yale University, Yale Depression Research Program - New Haven
Massachusetts
- Massachussettes General Hospital, Depression Clinical and Research Center - Boston
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2011-06 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
What the finished NCT01204918 record still lists
NCT01204918 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01204918 reports a single indexed study location in Connecticut, Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT01204918 about?
NCT01204918 is a clinical study titled "Efficacy and Tolerability of Riluzole in Treatment Resistant Depression". This study aims to examine the antidepressant efficacy of riluzole, employing a randomized, double-blind, placebo-controlled, adjunctive trial in treatment-resistant major depressive disorder (TRD).
What is the current status of trial NCT01204918?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2011-06. Estimated completion is 2015-08.
What conditions does trial NCT01204918 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT01204918?
The interventions under investigation include: placebo (DRUG), Riluzole (DRUG).
Who is sponsoring clinical trial NCT01204918?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01204918 being conducted?
This trial has 3 study locations across Connecticut, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01204918's enrollment target sits among peer trials
104 320th of 679 higher than 359 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia